Drug Profile
Lauflumide - NLS Pharmaceutics Ltd
Alternative Names: NLS-14; NLS-4Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator NeuroLifeSciences
- Developer NLS Pharmaceutics Ltd; University of Lausanne
- Class Behavioural disorder therapies; Benzhydryl compounds; Sleep disorder therapies; Small molecules
- Mechanism of Action Alpha 1 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Chronic fatigue syndrome
- No development reported Idiopathic hypersomnia
- Discontinued Alzheimer's disease; Attention-deficit hyperactivity disorder; Narcolepsy
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for preclinical development in Idiopathic-hypersomnia in Switzerland
- 09 Oct 2023 Discontinued - Preclinical for Narcolepsy in Switzerland (unspecified route) before October 2023 (NLS Pharmaceutics pipeline, October 2023)
- 09 Oct 2023 Preclinical trials in Chronic fatigue syndrome in Switzerland (unspecified route) before October 2023 (NLS Pharmaceutics pipeline, October 2023)